---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115850"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:52:01.389567+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quoin Q3 net loss $2.3M; initiates Peeling Skin Syndrome study; management buys shares

## Summary
- Net loss of $2.3M for Q3 2024 vs $1.9M in Q3 2023; nine-month net loss $6.7M vs $6.6M.
- Cash and equivalents $10.3M as of Sept 30, 2024; expected to fund operations into late 2025.
- Initiates investigator-led clinical study for QRX003 in Peeling Skin Syndrome in New Zealand; no approved treatments exist.
- Opens two additional UK sites for Netherton Syndrome trials under FDA IND; plans further European expansion.
- Entire management team made significant insider share purchases in September, signaling confidence in growth trajectory.

## SEC filing metadata
- accession: 0001104659-24-115850
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465924115850/0001104659-24-115850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465924115850/tm2427874d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115850
- JSON: https://secwatch.observer/filing/0001104659-24-115850.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.